[ 1 ] Lowenberg B, Downing JR, Burneett A. Acute myeloid leukemia[J]. N Engl J Med, 1999, 341(14): 1051-1062.
[2]
[ 2 ] Rowe JM. What is the best induction regimen for acute myelogenous leukemia [J]. Leukemia, 1998, 12(Suppl 1): S16-19.
[3]
[ 3 ] Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia[J]. Leuk Lymphoma, 2002, 43(2): 281-291.
[4]
[ 4 ] Aviv I, Irit R, Jacob M, et al. Acute lymphocytic leukemia: role of hematopoietic stem cell transplantion in current management[J]. Curr Opin Hematol, 2003, 10(6): 463-468.
[ 7 ] Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trial in acute myeloid leukemia[J]. J Clin Oncol, 2003, 21(24): 4642.
[8]
[ 8 ] G？kbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia[J]. Semin Hematol, 2009, 46(1): 44-75.
[9]
[ 9 ] Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature[J]. Leuk Lymphoma, 2002, 43(9): 1715-1727.
[10]
Miyawaki S, Hatsumi N, Yamauchi T. Phase 2 study of FLAGM (fludarabine+High-Dose Ara-C+G-CSF+Mitoxantrone) for relapsed or refractory acute myeloid leukemia (AML): a report frome the Japan adult leukemia study group (JALSG)[J]. Blood, 2009, 114(10): Abstract 2051.
Schirmer M, Stegmann AP, Geisen F, et al. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5’-nucleotidase activity[J]. Exp Hematol, 1998, 26(13): 1223-1228.
[13]
Angiolillo AL, Whitlock J, Chen Z, et al. PhaseⅡstudy of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a children’s oncology group report[J]. Pediatr Blood Cancer, 2006, 46(2): 193-197.
[14]
Steinherz PG, Seibel NL, Ames MM, et al. PhaseⅠ study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group[J]. Leuk lymphoma, 2002, 43(10): 1945-1950.
[15]
Rizzieri DA, Bass AJ, Rosner GL, et al. PhaseⅠ evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia[J]. J Clin Oncol, 2002, 20(3): 674-679.
[16]
Apostolidou E, Estey E, Cortes J, et al. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia[J]. Leuk Res, 2003, 27(4): 301-304.
[17]
Lee JH, Choi SJ, Lee JH, et al. Continuous infusion intermediate-dose cytarabine, mitoxantrone plus etoposide for refractory or early relapsed acute myelogenous leukemia[J]. Leuk Res, 2006, 30(2): 204-210.
